I'm LongbridgeAI, I can summarize articles.Lionco expects a net loss of approximately 120 million yuan for the year 2024, a reduction in loss of 20.79% compared to the same period last year. The main reason for the loss is the decline in gross profit due to centralized procurement, which has resulted in sales gross profit not covering the period expenses. Nevertheless, the company has significantly increased sales revenue compared to last year by promoting varieties that have won bids in centralized procurement, expanding sales of non-procurement products, and adjusting sales strategies. The sales performance of cardiovascular products is outstanding, while the company continues to promote refined management to reduce costs
According to the announcement from Lionco (603669.SH), the company expects to achieve a net loss attributable to the owners of the parent company of approximately 120 million yuan for the year 2024, representing a reduction in loss of about 20.79% compared to the same period last year (statutory disclosure data).
The main reason for the loss this period is the decline in gross profit caused by centralized procurement, where the sales gross profit could not cover the period expenses, leading to a loss in performance for this period. During the reporting period, after winning bids for centralized procurement products, the company entered an upward cycle of market expansion, increasing efforts to promote the products won through centralized procurement, resulting in a significant increase in sales revenue compared to the same period last year; fully utilizing channel advantages to promote non-procurement products in the market, expanding the sales scale of these products, increasing market share, adjusting sales strategies, and increasing sales channels in private hospitals, leading to a significant increase in sales revenue from cardiovascular products compared to the same period last year; continuously promoting refined management, exploring potential savings from multiple aspects, and taking effective measures to reduce and control cost expenditures; maximizing production capacity, fully leveraging capacity advantages, and actively seeking CMO orders, resulting in a significant decrease in losses compared to the same period last year